A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses
Recruiting · NCT06136403 · Registry updated 2025-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases, Skin Abnormalities, Skin and Connective Tissue Diseases, epidermolysis bullosa, epidermolysis bullosa simplex, hereditary disease, hereditary skin disorder, ichthyosis, keratosis, skin disorder, vesiculobullous skin disease | Recruiting | Phase 2 | 2025-08-05 | NCT06136403 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Centre Hospitalier Universitaire de Nice | 229 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| APHP St Louis | Paris | France | 1 |
| CHU de Nice | Nice | France | 5 |